Fibrogen | 10-Q: FY2025 Q3 Revenue: USD 1.076 M

Revenue: As of FY2025 Q3, the actual value is USD 1.076 M.

EPS: As of FY2025 Q3, the actual value is USD 49.61.

EBIT: As of FY2025 Q3, the actual value is USD -4.259 M.

Segment Revenue

• Development and Other Revenue: $119,000 for the three months ended September 30, 2025, compared to $385,000 for the same period in 2024, a decrease of 69%.
• Drug Product Revenue, Net: $957,000 for the three months ended September 30, 2025, compared to -$262,000 for the same period in 2024, an increase of 465%.

Operational Metrics

• Net Income (Loss): Net income of $200.6 million for the three months ended September 30, 2025, compared to a net loss of $17.1 million for the same period in 2024.
• Loss from Continuing Operations: Loss of $13.1 million for the three months ended September 30, 2025, compared to a loss of $48.3 million for the same period in 2024.
• Operating Costs and Expenses: $6.5 million for the three months ended September 30, 2025, compared to $47.8 million for the same period in 2024, a decrease of 86%.

Cash Flow

• Net Cash Provided by Operating Activities: $13.6 million for the nine months ended September 30, 2025, compared to net cash used of $107.5 million for the same period in 2024.
• Net Cash Provided by Investing Activities: $87.1 million for the nine months ended September 30, 2025, compared to $124.3 million for the same period in 2024.
• Net Cash Used in Financing Activities: $86.0 million for the nine months ended September 30, 2025, compared to $260,000 for the same period in 2024.

Unique Metrics

• Gain on Divestiture: $52.2 million gain from the divestiture of FibroGen International.

Future Outlook and Strategy

• Core Business Focus: FibroGen plans to continue the development of FG-3246 for metastatic castration-resistant prostate cancer and is preparing for a Phase 3 trial for roxadustat in anemia associated with lower-risk myelodysplastic syndromes, with a protocol submission to the FDA planned for the fourth quarter of 2025.
• Non-Core Business: The company completed the sale of its China operations to AstraZeneca, which included all roxadustat assets in China, for a total consideration of $220.4 million.